Skip to main content
Erschienen in: Investigational New Drugs 3/2011

01.06.2011 | PRECLINICAL STUDIES

Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan

verfasst von: Sergio Cafaggi, Eleonora Russo, Rossana Stefani, Brunella Parodi, Gabriele Caviglioli, Greta Sillo, Angela Bisio, Cinzia Aiello, Maurizio Viale

Erschienen in: Investigational New Drugs | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Summary

In this work, nanoparticles with a positive surface charge were prepared through the electrostatic interaction of a new cisplatin-hyaluronate complex with N-trimethyl chitosan (substitution degree of 85%). Mean particle diameter was approximately 195 nm. Drug loading of nanoparticles, which had a zeta potential of about 27 mV, was equal to 6% w/w. After 24 h, while the cisplatin-hyaluronate complex released approximately 60% w/w drug in phosphate buffered saline at pH 7.4, approximately 40% w/w of total cisplatin was released from nanoparticles. The same cumulative amounts of released drug were found after 48 h. These nanoparticles, as well as the starting cisplatin-hyaluronate complex, were active on all cell lines tested (P388, A2780, A549), with an antiproliferative activity similar to that of cisplatin. Apoptosis was markedly induced in A2780 cells by nanoparticles. In a preliminary in vivo experiment, the antitumour activity against a murine tumour (P388 cells) subcutaneously implanted in mice, resulted similar to that of cisplatin for nanoparticles whereas the starting complex showed a non-significant activity at the cisplatin dose tested. Body weight change of treated mice suggested a significantly better tolerance of the nanoparticles compared to cisplatin, after an initial brief period of acute toxicity higher than the parent drug. These results indicate that such a particulate system could be useful as a carrier for cisplatin delivery.
Literatur
1.
Zurück zum Zitat Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M (1989) Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res 9:1121–1128PubMed Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M (1989) Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res 9:1121–1128PubMed
2.
Zurück zum Zitat Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R (1999) Hpma copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 35:994–1002PubMedCrossRef Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R (1999) Hpma copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 35:994–1002PubMedCrossRef
3.
Zurück zum Zitat Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767–776PubMedCrossRef Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767–776PubMedCrossRef
4.
Zurück zum Zitat Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z (2006) Poly-(γ, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27:5958–5965PubMedCrossRef Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z (2006) Poly-(γ, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27:5958–5965PubMedCrossRef
5.
Zurück zum Zitat Schlechter B, Neumann A, Wilchek M, Arnon R (1989) Soluble polymers as carriers of cis-platinum. J Controll Release 10:75–87CrossRef Schlechter B, Neumann A, Wilchek M, Arnon R (1989) Soluble polymers as carriers of cis-platinum. J Controll Release 10:75–87CrossRef
6.
Zurück zum Zitat Imai T, Fujii K, Shiraishi S, Otagiri M (1997) Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J Pharm Sci 86:244–247PubMedCrossRef Imai T, Fujii K, Shiraishi S, Otagiri M (1997) Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J Pharm Sci 86:244–247PubMedCrossRef
7.
Zurück zum Zitat Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, De Totero D, Aiello C, Viale M (2007) Preparation and evaluation of nanoparticles made of chitosan or n-trimethyl chitosan and a cisplatin-alginate complex. J Controll Release 121:110–123CrossRef Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, De Totero D, Aiello C, Viale M (2007) Preparation and evaluation of nanoparticles made of chitosan or n-trimethyl chitosan and a cisplatin-alginate complex. J Controll Release 121:110–123CrossRef
8.
Zurück zum Zitat Avichezer D, Schechter B, Arnon R (1998) Functional polymers in drug delivery: carrier-supported cddp (cis-platin) complexes of polycarboxylates—effect on human ovarian carcinoma. Reactive Funct Polymers 36:59–69CrossRef Avichezer D, Schechter B, Arnon R (1998) Functional polymers in drug delivery: carrier-supported cddp (cis-platin) complexes of polycarboxylates—effect on human ovarian carcinoma. Reactive Funct Polymers 36:59–69CrossRef
9.
Zurück zum Zitat Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M (2006) Tumor cells enhance their own cd44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 281:5861–5868PubMedCrossRef Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M (2006) Tumor cells enhance their own cd44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 281:5861–5868PubMedCrossRef
10.
Zurück zum Zitat Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Therap 5:2139–2148CrossRef Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Therap 5:2139–2148CrossRef
11.
Zurück zum Zitat Ravi Kumar MNV (2001) A review of chitin and chitosan applications. Reactive Funct Polymers 46:1–27CrossRef Ravi Kumar MNV (2001) A review of chitin and chitosan applications. Reactive Funct Polymers 46:1–27CrossRef
12.
Zurück zum Zitat Calvo P, Remunan-Lopez C, Vila-jato JL, Alonso MJ (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–132CrossRef Calvo P, Remunan-Lopez C, Vila-jato JL, Alonso MJ (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–132CrossRef
13.
Zurück zum Zitat Mi FL, Sung HW, Shyu SS (2001) Release of indomethacin from a novel chitosan microsphere prepared by naturally occurring crosslinker: examination of crosslinking and polycation/anionic drug interaction. J Appl Polym Sci 81:1700–1711CrossRef Mi FL, Sung HW, Shyu SS (2001) Release of indomethacin from a novel chitosan microsphere prepared by naturally occurring crosslinker: examination of crosslinking and polycation/anionic drug interaction. J Appl Polym Sci 81:1700–1711CrossRef
14.
Zurück zum Zitat Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W (2006) Preparation and characterization of protein-loaded n-trimethyl chitosan nanoparticles as nasal delivery system. J Controll Release 111:107–116CrossRef Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W (2006) Preparation and characterization of protein-loaded n-trimethyl chitosan nanoparticles as nasal delivery system. J Controll Release 111:107–116CrossRef
15.
Zurück zum Zitat Hamman JH, Stander M, Kotzé AF (2002) Effect of the degree of quaternization of n-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 232:235–242PubMedCrossRef Hamman JH, Stander M, Kotzé AF (2002) Effect of the degree of quaternization of n-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 232:235–242PubMedCrossRef
16.
Zurück zum Zitat Lee J-K, Lim H-S, Kim J-H (2002) Cytotoxic activity of aminoderivatized cationic chitosan derivatives. Bioorg Med Chem Lett 12:2949–2951PubMedCrossRef Lee J-K, Lim H-S, Kim J-H (2002) Cytotoxic activity of aminoderivatized cationic chitosan derivatives. Bioorg Med Chem Lett 12:2949–2951PubMedCrossRef
17.
Zurück zum Zitat Kean T, Roth S, Thanou M (2005) Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Controll Release 103:643–653CrossRef Kean T, Roth S, Thanou M (2005) Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Controll Release 103:643–653CrossRef
18.
Zurück zum Zitat Haas J, Kumar MNVR, Borchard G, Bakowsky U, Lehr C-M (2005) Preparation and characterization of chitosan and trimethyl-chitosan modified poly-(ε-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech 6:E22–E30PubMedCrossRef Haas J, Kumar MNVR, Borchard G, Bakowsky U, Lehr C-M (2005) Preparation and characterization of chitosan and trimethyl-chitosan modified poly-(ε-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech 6:E22–E30PubMedCrossRef
19.
Zurück zum Zitat Russo E, Stefani R, Parodi B, Caviglioli G, Aiello C, Viale M, Cafaggi S, Bignardi G (2008) Cisplatin delivery: a study on a cisplatin-hyaluronate complex and nanoparticles formed by its interaction with n-trimethyl chitosan. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Barcelona Russo E, Stefani R, Parodi B, Caviglioli G, Aiello C, Viale M, Cafaggi S, Bignardi G (2008) Cisplatin delivery: a study on a cisplatin-hyaluronate complex and nanoparticles formed by its interaction with n-trimethyl chitosan. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Barcelona
20.
Zurück zum Zitat Jeong Y-I, Kim S-T, Jin S-G, Ryu H-H, Jin Y-H, Jung T-Y, Kim I-Y, Jung S (2008) Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 97:1268–1276PubMedCrossRef Jeong Y-I, Kim S-T, Jin S-G, Ryu H-H, Jin Y-H, Jung T-Y, Kim I-Y, Jung S (2008) Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 97:1268–1276PubMedCrossRef
21.
Zurück zum Zitat Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML (2008) Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 147:247–252PubMedCrossRef Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML (2008) Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 147:247–252PubMedCrossRef
22.
Zurück zum Zitat Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–353PubMedCrossRef Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–353PubMedCrossRef
23.
Zurück zum Zitat Lorenz MR, Holzapfel V, Musyanovych A, Nothelfer K, Walther P, Frank H, Landfester K, Schrezenmeier H, Mailander V (2006) Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 27:2820–2828PubMedCrossRef Lorenz MR, Holzapfel V, Musyanovych A, Nothelfer K, Walther P, Frank H, Landfester K, Schrezenmeier H, Mailander V (2006) Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 27:2820–2828PubMedCrossRef
24.
Zurück zum Zitat Lewis GA, Mathieu D, Phan-Tan-Luu R (1999) Pharmaceutical experimental design. Dekker, New York Lewis GA, Mathieu D, Phan-Tan-Luu R (1999) Pharmaceutical experimental design. Dekker, New York
25.
Zurück zum Zitat Hussain RF, Nouri AME, Oliver RTD (1993) A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160:89–96PubMedCrossRef Hussain RF, Nouri AME, Oliver RTD (1993) A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160:89–96PubMedCrossRef
26.
Zurück zum Zitat Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A (2006) A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia 20:785–792PubMedCrossRef Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A (2006) A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia 20:785–792PubMedCrossRef
27.
Zurück zum Zitat Drímalová E, Velebný V, Sasinková V, Hromádková Z, Ebringerová A (2005) Degradation of hyaluronan by ultrasonication in comparison to microwave and conventional heating. Carbohydr Polym 61:420–426CrossRef Drímalová E, Velebný V, Sasinková V, Hromádková Z, Ebringerová A (2005) Degradation of hyaluronan by ultrasonication in comparison to microwave and conventional heating. Carbohydr Polym 61:420–426CrossRef
28.
Zurück zum Zitat Cowman MK, Matsuoka S (2005) Experimental approaches to hyaluronan structure. Carbohydr Res 340:791–809PubMedCrossRef Cowman MK, Matsuoka S (2005) Experimental approaches to hyaluronan structure. Carbohydr Res 340:791–809PubMedCrossRef
29.
Zurück zum Zitat Hargittai I, Hargittai M (2008) Molecular structure of hyaluronan: an introduction. Struct Chem 19:697–717CrossRef Hargittai I, Hargittai M (2008) Molecular structure of hyaluronan: an introduction. Struct Chem 19:697–717CrossRef
30.
Zurück zum Zitat Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controll Release 70:399–421CrossRef Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controll Release 70:399–421CrossRef
31.
Zurück zum Zitat Verheul RJ, Amidi M, van Steenbergen MJ, van Riet E, Jiskoot W, Hennink WE (2009) Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials 30:3129–3135PubMedCrossRef Verheul RJ, Amidi M, van Steenbergen MJ, van Riet E, Jiskoot W, Hennink WE (2009) Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials 30:3129–3135PubMedCrossRef
32.
Zurück zum Zitat Furth G, Knierim R, Buss V, Mayer C (2008) Binding of bivalent cations by hyaluronate in aqueous solution. Int J Biol Macromol 42:33–40PubMedCrossRef Furth G, Knierim R, Buss V, Mayer C (2008) Binding of bivalent cations by hyaluronate in aqueous solution. Int J Biol Macromol 42:33–40PubMedCrossRef
33.
Zurück zum Zitat Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 98:2299–2316PubMedCrossRef Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 98:2299–2316PubMedCrossRef
34.
Zurück zum Zitat Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Controll Release 127:41–49CrossRef Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Controll Release 127:41–49CrossRef
35.
Zurück zum Zitat Kruczynski A, Hill BT (2001) Classic in vivo cancer models: Three examples of mouse models used in experimental therapeutics. Curr Protoc Pharmacol Unit 5.24:5.24.1–5.24.16 Kruczynski A, Hill BT (2001) Classic in vivo cancer models: Three examples of mouse models used in experimental therapeutics. Curr Protoc Pharmacol Unit 5.24:5.24.1–5.24.16
36.
Zurück zum Zitat Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaele D, Lepetre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, Ollivon M (2008) Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247–253PubMedCrossRef Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaele D, Lepetre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, Ollivon M (2008) Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247–253PubMedCrossRef
37.
Zurück zum Zitat Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55–64PubMedCrossRef Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55–64PubMedCrossRef
38.
Zurück zum Zitat Bankhead C (2006) Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? J Natl Cancer Inst 98:510–512PubMedCrossRef Bankhead C (2006) Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? J Natl Cancer Inst 98:510–512PubMedCrossRef
39.
Zurück zum Zitat Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against cd44(+) human ovarian carcinoma xenografts. Neoplasia 9:479–486PubMedCrossRef Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against cd44(+) human ovarian carcinoma xenografts. Neoplasia 9:479–486PubMedCrossRef
40.
Zurück zum Zitat Lee H, Lee K, Park TG (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 19:1319–1325PubMedCrossRef Lee H, Lee K, Park TG (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 19:1319–1325PubMedCrossRef
41.
Zurück zum Zitat Toole BP, Ghatak S, Misra S (2008) Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9:249–252PubMedCrossRef Toole BP, Ghatak S, Misra S (2008) Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9:249–252PubMedCrossRef
Metadaten
Titel
Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan
verfasst von
Sergio Cafaggi
Eleonora Russo
Rossana Stefani
Brunella Parodi
Gabriele Caviglioli
Greta Sillo
Angela Bisio
Cinzia Aiello
Maurizio Viale
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 3/2011
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9373-y

Weitere Artikel der Ausgabe 3/2011

Investigational New Drugs 3/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.